Therefore, we analyzed the cohort of all patients who have received chemoimmunotherapy for ES-SCLC at our institution since the approval of PD-L1 inhibitors as first-line treatment in addition to conventional palliative chemotherapy in patients with ES-SCLC in Germany in 2019. The gene discussed is CD274; the disease is small cell lung carcinoma.